home / stock / tals / tals message board
Subject | By | Source | When |
---|---|---|---|
Relative buying vol up 120Xs,one of highest in | 81vette | investorshub | 06/22/2023 3:55:26 PM |
Up 160% this year,6 month trend now revealed | 81vette | investorshub | 06/22/2023 3:38:13 PM |
Book pps 3.87,analysts target 7,50,GOLDEN CROSS!!,confirms bullish trend | 81vette | investorshub | 06/22/2023 3:20:29 PM |
210M cash coming,strong balance sheet.3 clinical trials,all phase 2 | 81vette | investorshub | 06/22/2023 3:08:56 PM |
Merger,900k short,shares to short dropping, 35%today,going to run | 81vette | investorshub | 06/22/2023 3:03:11 PM |
NEWS TALS Stock Alert: Halper Sadeh LLC Is Investigating | subslover | investorshub | 06/22/2023 1:27:58 PM |
2:27p ET 10/20/2022 - Benzinga | StockLogistics | investorshub | 12/28/2022 2:26:14 AM |
News, Short Squeeze, Breakout and More Instantly...
Talaris Therapeutics Inc. Company Name:
TALS Stock Symbol:
NASDAQ Market:
Combined Company to Trade on Nasdaq Under Ticker “TRML” Talaris Announces 1-for-10 Reverse Stock Split of Common Stock BOSTON, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) today announced the results of the special...
Special dividend estimated to be $1.5118 per share Payment of special dividend conditioned upon closing of merger, which is subject to stockholder approval BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris” or the “C...
NEW YORK and BOSTON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) announced today NYBCe’s acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, a...